Our Mission

Alta California Botanicals is a Biopharmaceutical company focused on developing protocols and products to relieve Clinical Endo Cannabinoid Deficiency (CECD)

We use the science of “synergetics” as articulated by R Buckminster Fuller to guide our understanding of the systems that produce Phytocannabinoids present in nature and their interaction with the Endo Cannabinoid Systems (ECS), present in all vertebrates.

Our worldly mission is to develop a health care system that works for 100% of humanity, in the shortest possible time. Through spontaneous cooperation of individuals, without ecological offense or to the disadvantage of anyone, we strongly believe this is not only possible but vital to humankind.

Our starting point, in 2010, was to introduce a "smokeless" alternative for medical cannabis patients. Recently we introduced the first "Cannabinoid Therapy" for treating those suffering from "treatment resistant" conditions such as Lyme's disease, Fibromyalgia, Migraines, etc. To read further about our accomplishments and contributions, visit our Time Line page by clicking here.

About the Products


Alta California Botanicals™ manufactures tinctures that are formulated by CBD Science, LLC, using scientific research and clinical data available in studies and US registered patents. Alta California Botanicals uses “systems and methods for producing organic cannabis tincture” outlined in the patent #US8445034.

Tinctures or Cannabis Based Medicinal Extracts (CBMEs)

Alta California Botanicals™ are 100% organic tinctures.  They are triple tested for maximum safety and effectiveness. Alta California Botanicals is the first to offer integrated cannabinoid therapy. We use the active ingredients present in the cannabis plant to combine THCA, THC, CBD, CBDA, CBN, and other cannabinoids in six product formulations. These are the minimum requirements for managing your endocannabinoid system. 

These tinctures also known as Cannabis Based Medical Extracts (CBMEs) are made from selected strains of organic cannabis plants cultivated using safe cannabis practices. Our tinctures are available at licensed dispensaries throughout California.  Every batch is triple tested for maximum safety and effectiveness.  Lab results for all three stages of testing can be found online at www.SCLabs.com. All phases of manufacturing are controlled and standardized for approximate dosage. Consistent extraction and controlled blending, makes these botanical substances safe. Legally grown from selected organic cannabis, these CBMEs are standardized and made in accordance with modern hygienic standards.

How do cannabinoids work?

The pharmacological effects of cannabinoids are due to the endocannabinoid system. The endocannabinoid system is responsible for homeostatic balance in all vertebrates.
 

 

 

Cannabinoids are produced in Three Stages; "Early, Middle and Late"

Cannabinoids can be found in Three Chemical Compounds Acids, Neutrals and Metabolites.

The acidic cannabinoids (THCA. CBDA, CBCA, and CBGA ) are the primary anti-inflammation agents in the cannabis plant. They build your Endocannabinoid System. Specifically, they regulate the enzymes that give rise to inflammation, COX-1, COX-2, Interluten 10 and TNF (a). They can be taken orally, topically, or by suppository.

The method of operation of the acidic cannabinoids is contained in patent #US7807711 entitled the "Medicinal Acidic Cannabinoids".

The neutral cannabinoids (THC, CBD, CBC, and CBG) manage your endocannabinoid system via the CB1, CB2 receptors. These receptors are located in immune tissues and organs throughout the body. The Endocannabinoid System interacts with many other neurotransmitters and neuromodulator systems.

 

The metabolite cannabinoids (CBN, CBS, and CBL) sedate your Endocannabinoid System by turning the cell activity off.  The capacity to sedate the system is why it is an effective insomnia relief agent.

Primary focus

Clinical Endocannabinoid Deficiency

In 2004 Ethan Russo first hypothesized the existence of Clinical Endocannabinoid Deficiency with his ground breaking paper entitled “Clinical Endocannabinoid Deficiency (CECD).” Dr. Russo hypothesis is that “treatment resistant” conditions exist because we are suffering from a deficiency of cannabinoids. The research was repeated in 2010 and 2014 and both times the hypothesis was valid.

Primary Contribution

Cannabinoid Therapy for CECD

Alta California Botanicals™ is the first to offer a rigorous protocol for treating Clinical Endocannabinoid Deficiency (CECD).  For more details visit the “Learn” tab on this webpage.